Triapine (3-AP)

Triapine (3-AP) 是一种强效的ribonucleotide reductase (RNR)抑制剂,通过抑制DNA的合成而具有广谱抗肿瘤活性。

Triapine (3-AP) Chemical Structure

Triapine (3-AP) Chemical Structure

CAS: 200933-27-3

规格 价格 库存 购买数量
10mM (1mL in DMSO) 997 现货
10mg 811.33 现货
25mg 1933.42 现货
100mg 5561.01 现货
1g 24488.1 现货
更大包装 有超大折扣

400-668-6834

info@selleck.cn

免费分装
免费预溶

Triapine (3-AP)相关产品

细胞实验数据示例

细胞系 实验类型 给药浓度 孵育时间 活性描述 文献信息(PMID)
HCT116 Function assay 4 uM 24 hrs Induction of ROS generation in human HCT116 cells expressing wild type p53 at 4 uM after 24 hrs by spectrophotometry 24900837
SW480 Function assay 2.5 uM 48 hrs Induction of morphological changes in human SW480 cells assessed as induction of massive cell flattening at 2.5 uM incubated for 48 hrs by phase contrast microscopy 27336684
HL60 Function assay 1 and 5 uM 30 mins Induction of intracellular ROS generation in human HL60 cells at 1 and 5 uM in presence of CuCl2 incubated for 30 mins by DCF-DA staining based fluorescence assay 27336684
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50=0.26μM 17602603
KB-3-1 Cytotoxicity assay 72 hrs Cytotoxicity against human P-gp-negative KB-3-1 cells after 72 hrs by MTT assay, IC50=1.4μM 19397322
KB-3-1 Cytotoxicity assay 72 hrs Cytotoxicity against human P-gp-negative KB-3-1 cells after 72 hrs by MTT assay, IC50=1.41254μM 19397322
KBV1 Cytotoxicity assay 72 hrs Cytotoxicity against human P-glycoprotein-expressing KBV1 cells after 72 hrs by MTT assay, IC50=5.88844μM 19397322
KBV1 Cytotoxicity assay 72 hrs Cytotoxicity against human P-glycoprotein-expressing KBV1 cells after 72 hrs by MTT assay, IC50=5.9μM 19397322
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50=0.26μM 19601577
HCT116 Dark cytotoxicity assay 96 hrs Dark cytotoxicity against human HCT116 cells expressing wild type p53 after 96 hrs by MTT assay, IC50=1.226μM 24900837
HCT116 Photocytotoxicity assay 24 hrs Photocytotoxicity against human HCT116 cells expressing wild type p53 incubated for 24 hrs followed by light irradiation measured after 24 hrs by MTS assay in presence of ALA and FeCl3 24900837
KB-3-1 Cytotoxicity assay 72 hrs Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay, IC50=3.1μM 27336684
KBC1 Cytotoxicity assay 72 hrs Cytotoxicity against human KBC1 cells incubated for 72 hrs by MTT assay, IC50=8.9μM 27336684
WPMY-1 Antiproliferative assay 72 hrs Antiproliferative activity against human WPMY-1 cells assessed as reduction in cell proliferation incubated for 72 hrs by MTT assay, IC50=4.96μM 31614257
GES-1 Antiproliferative assay 72 hrs Antiproliferative activity against human GES-1 cells assessed as reduction in cell proliferation incubated for 72 hrs by MTT assay, IC50=5.6μM 31614257
GES-1 Cytotoxicity assay 72 hrs Cytotoxicity against human GES-1 cells after 72 hrs by MTT assay, IC50=5.4μM ChEMBL
MGC803 Antiproliferative assay 72 hrs Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay, IC50=9.68μM ChEMBL
MCF7 Antiproliferative assay 72 hrs Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, IC50=18.85μM ChEMBL
SMMC7721 Antiproliferative assay 72 hrs Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay, IC50=42.81μM ChEMBL
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 18159922
SK-N-MC Antiproliferative assay Antiproliferative activity against human SK-N-MC cells by MTT assay, IC50=0.54μM 17963372
SK-N-MC Antiproliferative assay Antiproliferative activity against human SK-N-MC cells by MTT assay, IC50=0.31μM 17142046
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 27336684
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 27336684
L1210 Growth inhibition assay Growth inhibition of mouse L1210 cells by MTS assay, IC50=1.3μM 30904782
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 31614257
HEK293 Cytotoxicity assay Cytotoxicity against HEK293 cells (CO-ADD:MA_007); CC50 by cell viability assay in DMEM (10% FBS) media using TC plates, by Resazurin F(560/590), CC50=2.827μM ChEMBL
点击查看更多细胞系数据

生物活性

产品描述 Triapine (3-AP) 是一种强效的ribonucleotide reductase (RNR)抑制剂,通过抑制DNA的合成而具有广谱抗肿瘤活性。
靶点
Ribonucleotide reductase
体外研究(In Vitro)
体外研究活性 在野生型KB和HU-抗性KB的鼻咽癌细胞中,Triapine抑制核苷酸还原酶的活性。在一系列的肿瘤细胞系中,Triapine通过抑制DNA合成具有广谱的抗肿瘤活性。在体外实验中,Triapine阻断缺血性的神经毒性和低氧毒性,其EC50分别是0.35 μM 和 0.75 μM。Triapine通过抑制神经毒剂,包括星状孢菌素,藜芦定和 谷氨酸等诱导的细胞死亡,表现出神经保护活性。
激酶实验 核糖核苷酸还原酶实验
CDP还原酶通过Dowex 1-borate离子交换色谱测定。实验体系包含0.02 μCi [14C]CDP (52.9 mCi/mmol), 3 mM 二硫苏糖醇,6 mM MgCl2,30 mM HEPES,5 mM ATP,0.15 mM 未标记的CDP,以及10 μL 细胞提取物,终体积为0.02 毫升。反应的培养时间为60分钟,反应和时间呈线性关系。
细胞实验 细胞系 野生型KB和HU抵性KB鼻咽癌
浓度 ~10 μM
孵育时间 第3代时期
方法

细胞以104每孔的密度接种于24孔板上,药物加入到细胞中,连续培养3代(未经处理的对照细胞),随后用亚甲基蓝试验测定细胞生长。

实验图片 检测方法 检测指标 实验图片 PMID
Western blot p-Chk1 / Chk1 / p-CDK1/2 / CDK1/2 / p-H1 24413181
Growth inhibition assay Cell viability 31118677
体内研究(In Vivo)
体内研究活性 在有L1210白血病的小鼠中,Triapine (1.25~20 毫克/千克)能够治疗一些小鼠且没有致命毒性。Triapine同时抑制小鼠M109 肺癌和人 A2780 卵巢癌的肿瘤生长。此外,联合使用Triapine和其它的损伤DNA的抑制剂能够对L1210 白血病协同抑制。在大鼠瞬时缺血模型中,当(50 μ 每只大鼠)注射时,Triapine 减少59%的梗死体积,静脉注射(1 毫克/千克)时,减少35%的梗死体积。
动物实验 Animal Models 患有L1210白血病和 M109肺肿瘤的BALB/cBA/2 (CD2F1)小鼠,异种移植人A2780卵巢癌的无胸腺nu/nu小鼠。
Dosages ~24毫克/千克
Administration 腹腔注射或静脉注射
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06410248 RECRUITING
Recurrent Glioblastoma, IDH-Wildtype; Recurrent WHO Grade 2 Glioma; Recurrent WHO Grade 3 Glioma; Recurrent WHO Grade 4 Glioma
Northwestern University
2024-07-23 PHASE1
NCT06860594 RECRUITING
Astrocytoma, IDH-Mutant, Grade 2; Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant; Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant; Recurrent Astrocytoma, IDH-Mutant; Recurrent Astrocytoma, IDH-Mutant, Grade 3; Recurrent Astrocytoma, IDH-Mutant, Grade 4; Recurrent Glioblastoma, IDH-Wildtype
National Cancer Institute (NCI)
2025-07-30 PHASE1
NCT05724108 ACTIVE_NOT_RECRUITING
Metastatic Neuroendocrine Tumor
National Cancer Institute (NCI)
2023-08-30 PHASE2
NCT04494113 ACTIVE_NOT_RECRUITING
Endometrial Serous Adenocarcinoma
National Cancer Institute (NCI)
2022-02-08 EARLY_PHASE1
NCT04234568 ACTIVE_NOT_RECRUITING
Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Neuroendocrine Tumor
National Cancer Institute (NCI)
2020-07-20 PHASE1
NCT02595879 ACTIVE_NOT_RECRUITING
Advanced Cervical Adenocarcinoma; Advanced Cervical Adenosquamous Carcinoma; Advanced Cervical Squamous Cell Carcinoma; Advanced Vaginal Adenocarcinoma; Advanced Vaginal Adenosquamous Carcinoma; Advanced Vaginal Squamous Cell Carcinoma; Stage IB2 Cervical Cancer AJCC v6 and v7; Stage II Cervical Cancer AJCC v7; Stage II Vaginal Cancer AJCC v6 and v7; Stage III Vaginal Cancer AJCC v6 and v7; Stage IIIB Cervical Cancer AJCC v6 and v7; Stage IVA Cervical Cancer AJCC v6 and v7; Stage IVA Vaginal Cancer AJCC v6 and v7
National Cancer Institute (NCI)
2019-09-18 PHASE1
  • [1]https://pubmed.ncbi.nlm.nih.gov/10692563/
  • [2]https://pubmed.ncbi.nlm.nih.gov/16834759/

化学信息&溶解度

分子量 195.24 分子式

C7H9N5S

CAS号 200933-27-3 SDF Download Triapine (3-AP) SDF
Smiles C1=CC(=C(N=C1)C=NNC(=S)N)N
储存条件(自收到货起) 3 years -20°C powder
1 year -20°C in 10mM/1mL

体外溶解度
批次:

DMSO : 39 mg/mL ( (199.75 mM) ;DMSO吸湿会降低化合物溶解度,请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解配方
批次:

现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量 浓度 体积 分子量

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL 只

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:取μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:取μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们
在线咨询
联系我们